Market News & Trends
Oncologie Announces Clinical Trial Collaboration With Merck
Oncologie, Inc. recently announced it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the…
Mustang Bio Announces $9.28-Million Grant to Fund Phase 1 Trial
Mustang Bio, Inc. recently announced that City of Hope has received a $9.28-million grant from the California Institute for Regenerative Medicine (CIRM) to fund an…
Preliminary Data Confirm Saphyr’s Potential to Replace Traditional Cytogenetics Methods
Bionano Genomics, Inc. recently announced a summary of results from two key studies presented this week at the 2019 Cancer Genomics Consortium Annual Meeting in…
Prostate Cancer Treatment Moving Toward Personalized Approach With 6 New Drugs in the Pipeline
Although options for prostate cancer have historically been limited, the late-stage prostate cancer pipeline holds promise for the future of this second most common cancer…
Cytovation & SMS-oncology Sign Agreement on Conduct of Phase 1/2 Trial
Cytovation AS and Specialized Medical Services-oncology BV recently announce that SMS-oncology has been selected as the CRO to conduct the Phase 1/2 clinical trial with…
INmune Bio Reports Positive Preliminary Data from INB03 Phase 1 Clinical Trial
INmune Bio, Inc. recently reported positive preliminary data during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston. INB03 is being developed…
Aquinox Pharmaceuticals & Neoleukin Therapeutics Announce Merger Agreement
Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. recently announced the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition…
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase 3 Study
Celsion Corporation recently announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase 3 Study with…
Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Eureka Therapeutics, Inc. recently announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS T-cell therapy in liver cancer at City of Hope, a world-renowned…
Cytel Launches East On Demand Bringing Adaptive Clinical Trial Design Capabilities to Wider Biopharma Audience
Cytel Inc. recently announced that it will launch East On Demand at the annual Joint Statistical Meetings (JSM) 2019 (July 27-August 1, Denver, CO). Offered…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….